PAVmed (PAVM) Q1 2026 Results: EPS Miss, Liquidity Risks

Font: Financial Modeling Prep  • May 15, 2026

PAVmed Inc. (NASDAQ: PAVM) Q1 2026 Results: EPS Miss, Minimal Revenue, and Ongoing Liquidity Risks

• PAVmed Inc. reported a Q1 2026 GAAP loss of $(4.42) per diluted share, missing analyst expectations.
• The company reported Q1 2026 revenue of only $22,000. Revenue increased from $8,000 in the prior-year quarter.
• PAVmed ended the quarter with $6.5 million in cash and cash equivalents, up from $1.5 million at year-end 2025.
• The company’s current ratio was approximately 2.02, but PAVmed continued to report recurring losses, negative cash flow from operations, and going-concern uncertainty.

PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its businesses include Veris Health, which is focused on cancer-care remote patient monitoring, and Lucid Diagnostics, a cancer-prevention diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device.

For the first quarter ended March 31, 2026, PAVmed reported revenue of $22,000, compared with $8,000 in the prior-year quarter. The company’s operating expenses were $8.1 million, including general and administrative expenses of $6.4 million and research and development expenses of $1.4 million.

PAVmed reported a GAAP net loss attributable to common stockholders of approximately $7.0 million, or $(4.42) per diluted share. The company’s non-GAAP adjusted net loss was approximately $1.9 million, or $(1.17) per share.